001     156842
005     20240229123118.0
024 7 _ |a 10.1158/1078-0432.CCR-20-0103
|2 doi
024 7 _ |a pmid:32554541
|2 pmid
024 7 _ |a 1078-0432
|2 ISSN
024 7 _ |a 1557-3265
|2 ISSN
024 7 _ |a altmetric:84192504
|2 altmetric
037 _ _ |a DKFZ-2020-01159
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Talhouk, Aline
|0 0000-0001-7760-410X
|b 0
245 _ _ |a Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE).
260 _ _ |a Philadelphia, Pa. [u.a.]
|c 2020
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1606134138_2611
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Oct 15;26(20):5411-5423
520 _ _ |a Gene-expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by non-standardized methods which are not applicable in a clinical setting. We sought to generate a clinical-grade minimal gene-set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features.Adopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene-expression data from 1650 tumors. We applied resulting models to NanoString data on 3829 HGSOCs from the Ovarian Tumor Tissue Analysis Consortium. We further developed, confirmed, and validated a reduced, minimal gene-set predictor, with methods suitable for a single patient setting.Gene-expression data was used to derive the Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor infiltrating lymphocytes, and outcome. The locked-down clinical-grade PrOTYPE test includes a model with 55 genes that predicted gene-expression subtype with >95% accuracy that was maintained in all analytical and biological validations.We validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical-grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a George, Joshy
|0 0000-0001-8510-8229
|b 1
700 1 _ |a Wang, Chen
|0 0000-0003-2638-3081
|b 2
700 1 _ |a Budden, Timothy
|b 3
700 1 _ |a Tan, Tuan Zea
|0 0000-0001-6624-1593
|b 4
700 1 _ |a Chiu, Derek S
|b 5
700 1 _ |a Kommoss, Stefan
|b 6
700 1 _ |a Leong, Huei San
|b 7
700 1 _ |a Chen, Stephanie
|b 8
700 1 _ |a Intermaggio, Maria P
|b 9
700 1 _ |a Gilks, Blake
|b 10
700 1 _ |a Nazeran, Tayyebeh Mehrane
|b 11
700 1 _ |a Volchek, Mila
|b 12
700 1 _ |a Elatre, Wafaa
|b 13
700 1 _ |a Bentley, Rex C
|b 14
700 1 _ |a Senz, Janine
|b 15
700 1 _ |a Lum, Amy
|b 16
700 1 _ |a Chow, Veronica
|b 17
700 1 _ |a Sudderuddin, Hanwei
|b 18
700 1 _ |a Mackenzie, Robertson
|b 19
700 1 _ |a Leung, Samuel
|b 20
700 1 _ |a Liu, Geyi
|b 21
700 1 _ |a Johnson, Dustin
|b 22
700 1 _ |a Chen, Billy
|b 23
700 1 _ |a Ovarian Cancer Study, Australian
|b 24
700 1 _ |a Alsop, Jennifer
|b 25
700 1 _ |a Banerjee, Susana
|b 26
700 1 _ |a Behrens, Sabine
|0 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
|b 27
|u dkfz
700 1 _ |a Bodelon, Clara
|0 0000-0002-6578-2678
|b 28
700 1 _ |a Brand, Alison H
|b 29
700 1 _ |a Brinton, Louise A
|0 0000-0003-3853-8562
|b 30
700 1 _ |a Carney, Michael E
|b 31
700 1 _ |a Chiew, Yoke-Eng
|b 32
700 1 _ |a Cushing-Haugen, Kara L
|b 33
700 1 _ |a Cybulski, Cezary
|b 34
700 1 _ |a Ennis, Darren
|b 35
700 1 _ |a Fereday, Sian
|b 36
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 37
|u dkfz
700 1 _ |a García-Donás, Jesus
|0 0000-0001-7731-3601
|b 38
700 1 _ |a Gentry-Maharaj, Aleksandra
|0 0000-0001-7270-9762
|b 39
700 1 _ |a Glasspool, Rosalind
|0 0000-0002-5000-1680
|b 40
700 1 _ |a Goranova, Teodora
|b 41
700 1 _ |a Greene, Casey S
|0 0000-0001-8713-9213
|b 42
700 1 _ |a Haluska, Paul
|b 43
700 1 _ |a Harris, Holly R
|0 0000-0002-2572-6727
|b 44
700 1 _ |a Hendley, Joy
|b 45
700 1 _ |a Hernandez, Brenda Y
|b 46
700 1 _ |a Herpel, Esther
|b 47
700 1 _ |a Jimenez-Linan, Mercedes
|b 48
700 1 _ |a Karpinskyj, Chloe
|b 49
700 1 _ |a Kaufmann, Scott Harold
|0 0000-0002-4900-7145
|b 50
700 1 _ |a Keeney, Gary
|b 51
700 1 _ |a Kennedy, Catherine J
|0 0000-0002-4465-5784
|b 52
700 1 _ |a Köbel, Martin
|0 0000-0002-6615-2037
|b 53
700 1 _ |a Koziak, Jennifer
|0 0000-0001-5830-0397
|b 54
700 1 _ |a Larson, Melissa C
|b 55
700 1 _ |a Lester, Jenny
|b 56
700 1 _ |a Lewsley, Liz-Anne
|b 57
700 1 _ |a Lissowska, Jolanta
|0 0000-0003-2695-5799
|b 58
700 1 _ |a Lubiński, Jan
|b 59
700 1 _ |a Luk, Hugh
|b 60
700 1 _ |a Macintyre, Geoff
|b 61
700 1 _ |a Mahner, Sven
|b 62
700 1 _ |a McNeish, Iain A
|0 0000-0002-9387-7586
|b 63
700 1 _ |a Menkiszak, Janusz
|0 0000-0001-8279-7196
|b 64
700 1 _ |a Nevins, Nikilyn
|b 65
700 1 _ |a Osorio, Ana
|b 66
700 1 _ |a Oszurek, Oleg
|b 67
700 1 _ |a Palacios, Jose
|b 68
700 1 _ |a Hinsley, Samantha
|0 0000-0001-6903-4688
|b 69
700 1 _ |a Pearce, Celeste L
|b 70
700 1 _ |a Pike, Malcolm C
|0 0000-0003-4891-1199
|b 71
700 1 _ |a Piskorz, Anna
|b 72
700 1 _ |a Ray-Coquard, Isabelle
|b 73
700 1 _ |a Rhenius, Valerie
|b 74
700 1 _ |a Rodríguez-Antona, Cristina
|0 0000-0001-8750-7338
|b 75
700 1 _ |a Sharma, Raghwa
|b 76
700 1 _ |a Sherman, Mark E
|b 77
700 1 _ |a Silva, Dilrini
|b 78
700 1 _ |a Singh, Naveena
|b 79
700 1 _ |a Sinn, Hans-Peter
|0 0000-0003-2836-6699
|b 80
700 1 _ |a Slamon, Dennis J
|b 81
700 1 _ |a Song, Honglin
|b 82
700 1 _ |a Steed, Helen
|b 83
700 1 _ |a Stronach, Euan A
|b 84
700 1 _ |a Thompson, Pamela J
|b 85
700 1 _ |a Tołoczko-Grabarek, Aleksandra
|b 86
700 1 _ |a Trabert, Britton
|0 0000-0002-1539-6090
|b 87
700 1 _ |a Traficante, Nadia
|b 88
700 1 _ |a Tseng, Chiu-Chen
|b 89
700 1 _ |a Widschwendter, Martin
|0 0000-0002-7778-8380
|b 90
700 1 _ |a Wilkens, Lynne R
|b 91
700 1 _ |a Winham, Stacey J
|0 0000-0002-8492-9102
|b 92
700 1 _ |a Winterhoff, Boris J
|b 93
700 1 _ |a Beeghly-Fadiel, Alicia
|b 94
700 1 _ |a Benitez, Javier
|b 95
700 1 _ |a Berchuck, Andrew
|b 96
700 1 _ |a Brenton, James D
|0 0000-0002-5738-6683
|b 97
700 1 _ |a Brown, Robert
|0 0000-0001-7960-5755
|b 98
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 99
|u dkfz
700 1 _ |a Chenevix-Trench, Georgia
|b 100
700 1 _ |a DeFazio, Anna
|0 0000-0003-0057-4744
|b 101
700 1 _ |a Fasching, Peter A
|0 0000-0003-4885-8471
|b 102
700 1 _ |a Garcia, Maria J
|b 103
700 1 _ |a Gayther, Simon A
|b 104
700 1 _ |a Goodman, Marc T
|b 105
700 1 _ |a Gronwald, Jacek
|b 106
700 1 _ |a Henderson, Michelle J
|b 107
700 1 _ |a Karlan, Beth Y
|b 108
700 1 _ |a Kelemen, Linda E
|0 0000-0003-4362-9784
|b 109
700 1 _ |a Menon, Usha
|0 0000-0003-3708-1732
|b 110
700 1 _ |a Orsulic, Sandra
|b 111
700 1 _ |a Pharoah, Paul D P
|0 0000-0001-8494-732X
|b 112
700 1 _ |a Wentzensen, Nicolas
|b 113
700 1 _ |a Wu, Anna H
|b 114
700 1 _ |a Shildkraut, Joellen
|b 115
700 1 _ |a Rossing, Mary Anne
|b 116
700 1 _ |a Konecny, Gottfried E
|b 117
700 1 _ |a Huntsman, David G
|b 118
700 1 _ |a Huang, Ruby Yun-Ju
|b 119
700 1 _ |a Goode, Ellen L
|b 120
700 1 _ |a Ramus, Susan J
|0 0000-0003-0005-7798
|b 121
700 1 _ |a Doherty, Jennifer A
|0 0000-0002-1454-8187
|b 122
700 1 _ |a Bowtell, David D L
|b 123
700 1 _ |a Anglesio, Michael S
|0 0000-0003-1639-5003
|b 124
773 _ _ |a 10.1158/1078-0432.CCR-20-0103
|g p. clincanres.0103.2020 -
|0 PERI:(DE-600)2036787-9
|n 20
|p 5411-5423
|t Clinical cancer research
|v 26
|y 2020
|x 1557-3265
909 C O |o oai:inrepo02.dkfz.de:156842
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 37
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 99
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN CANCER RES : 2018
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-06
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CLIN CANCER RES : 2018
|d 2020-01-06
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21